Univariate analysis comparing patient demographic characteristics, pathologic features and stage between endometrial cancers staged in the 2 years before the COVID-19 pandemic and in the first year of the pandemic
| Variable | No. (%)of cases* | Standardized difference | Stochastic dominance | OR (95% CI) | |
|---|---|---|---|---|---|
| 2 years before pandemic n = 391 | First year of pandemic n = 190 | ||||
| No. of cases per 30 d, mean | 16.1 | 15.6 | NA | ||
| Age, median (IQR), yr | 65 (59–72) | 66 (58–72) | 0.012 | – | NA |
| Histologic subtype | |||||
| Endometrioid carcinoma, NOS | 244 (62.7) | 112 (58.9) | 0.149 | – | 0.86 (0.61–1.23) |
| Endometrioid carcinoma, other variant | 56 (14.4) | 31 (16.3) | 1.17 (0.72–1.88) | ||
| High-grade | 88 (22.6) | 47 (24.7) | 1.13 (0.75–1.70) | ||
| Other | 3 | 0 | |||
| Histologic grade | |||||
| Low | 272 (69.6) | 125 (65.8) | 0.081 | 0.519 | 0.84 (0.58–1.22) |
| High | 119 (30.4) | 65 (34.2) | 1.19 (0.82–1.72) | ||
| Lymphovascular invasion | 115 (29.4) | 64 (33.7) | 0.092 | 0.521 | 1.22 (0.84–1.77) |
| Positive margin | 6 (1.5) | 3 (1.6) | 0.004 | 0.500 | 1.07 (0.26–4.32) |
| Stage | |||||
| I | 289 (73.9) | 145 (76.3) | – | 0.491 | NA |
| II | 38 (9.7) | 13 (6.8) | |||
| III + IV† | 64 (16.4) | 32 (16.8) | |||